Essais liés2clinical trials
VilleRizhaolocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT03963232

Ouvrir le site du centre

Essais cliniques associés

2
MoléculeIndication / populationPhaseNCTTitreStatut
Rimegepant Migraine Phase 3 NCT05810038 A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects. COMPLETED
Galcanezumab Migraine Phase 3 NCT03963232 PERSIST — A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine COMPLETED